Last reviewed · How we verify
standard saline infusion
Standard saline infusion replaces fluid and electrolytes lost through dehydration, illness, or medical procedures by delivering a balanced sodium chloride solution intravenously.
Standard saline infusion replaces fluid and electrolytes lost through dehydration, illness, or medical procedures by delivering a balanced sodium chloride solution intravenously. Used for Hypovolemia and dehydration, Perioperative fluid maintenance, Electrolyte replacement.
At a glance
| Generic name | standard saline infusion |
|---|---|
| Also known as | saline infusion |
| Sponsor | University of Roma La Sapienza |
| Drug class | Crystalloid fluid replacement |
| Modality | Small molecule |
| Therapeutic area | Supportive Care / Fluid Management |
| Phase | FDA-approved |
Mechanism of action
Normal saline (0.9% sodium chloride) is an isotonic crystalloid solution that maintains osmotic balance with blood plasma. It restores intravascular volume, supports tissue perfusion, and maintains electrolyte homeostasis. Saline has no active pharmacological mechanism but serves as a foundational fluid replacement therapy.
Approved indications
- Hypovolemia and dehydration
- Perioperative fluid maintenance
- Electrolyte replacement
- Vehicle for intravenous medication delivery
Common side effects
- Hyperchloremic acidosis
- Fluid overload / pulmonary edema
- Hypernatremia
- Phlebitis at infusion site
Key clinical trials
- Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older (PHASE2)
- Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction (PHASE2)
- Ketamine Treatment of Youth Suicide Attempters (PHASE3)
- Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases (PHASE2)
- Mannitol Versus Nitroglycerin for Kidney Injury Prevention in Robotic-assisted Radical Prostatectomy or Cystectomy (NA)
- Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG) (PHASE1)
- A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- standard saline infusion CI brief — competitive landscape report
- standard saline infusion updates RSS · CI watch RSS
- University of Roma La Sapienza portfolio CI